Managing Chemotherapy-Related Cardiotoxicity in Survivors of Childhood Cancers

Steven E Lipshultz, Melissa B. Diamond, Vivian I. Franco, Sanjeev Aggarwal, Kasey Leger, Maria Verônica Santos, Stephen E. Sallan, Eric J. Chow

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

In the US, children diagnosed with cancer are living longer, but not without consequences from the same drugs that cured their cancer. In these patients, cardiovascular disease is the leading cause of non-cancer-related morbidity and mortality. Although this review focuses on anthracycline-related cardiomyopathy in childhood cancer survivors, the global lifetime risk of other cardiovascular diseases such as atherosclerosis, arrhythmias and intracardiac conduction abnormalities, hypertension, and stroke also are increased. Besides anthracyclines, newer molecularly targeted agents, such as vascular endothelial growth factor receptor and tyrosine kinase inhibitors, also have been associated with acute hypertension, cardiomyopathy, and increased risk of ischemic cardiac events and arrhythmias, and are summarized here. This review also covers other risk factors for chemotherapy-related cardiotoxicity (including both modifiable and non-modifiable factors), monitoring strategies (including both blood and imaging-based biomarkers) during and following cancer treatment, and discusses the management of cardiotoxicity (including prevention strategies such as cardioprotection by use of dexrazoxane).

Original languageEnglish
Pages (from-to)373-389
Number of pages17
JournalPediatric Drugs
Volume16
Issue number5
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Survivors
Drug Therapy
Anthracyclines
Cardiomyopathies
Cardiac Arrhythmias
Neoplasms
Cardiovascular Diseases
Dexrazoxane
Hypertension
Vascular Endothelial Growth Factor Receptor
Protein-Tyrosine Kinases
Atherosclerosis
Biomarkers
Stroke
Morbidity
Mortality
Cardiotoxicity
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pharmacology (medical)

Cite this

Lipshultz, S. E., Diamond, M. B., Franco, V. I., Aggarwal, S., Leger, K., Santos, M. V., ... Chow, E. J. (2014). Managing Chemotherapy-Related Cardiotoxicity in Survivors of Childhood Cancers. Pediatric Drugs, 16(5), 373-389. https://doi.org/10.1007/s40272-014-0085-1

Managing Chemotherapy-Related Cardiotoxicity in Survivors of Childhood Cancers. / Lipshultz, Steven E; Diamond, Melissa B.; Franco, Vivian I.; Aggarwal, Sanjeev; Leger, Kasey; Santos, Maria Verônica; Sallan, Stephen E.; Chow, Eric J.

In: Pediatric Drugs, Vol. 16, No. 5, 01.01.2014, p. 373-389.

Research output: Contribution to journalArticle

Lipshultz, SE, Diamond, MB, Franco, VI, Aggarwal, S, Leger, K, Santos, MV, Sallan, SE & Chow, EJ 2014, 'Managing Chemotherapy-Related Cardiotoxicity in Survivors of Childhood Cancers', Pediatric Drugs, vol. 16, no. 5, pp. 373-389. https://doi.org/10.1007/s40272-014-0085-1
Lipshultz SE, Diamond MB, Franco VI, Aggarwal S, Leger K, Santos MV et al. Managing Chemotherapy-Related Cardiotoxicity in Survivors of Childhood Cancers. Pediatric Drugs. 2014 Jan 1;16(5):373-389. https://doi.org/10.1007/s40272-014-0085-1
Lipshultz, Steven E ; Diamond, Melissa B. ; Franco, Vivian I. ; Aggarwal, Sanjeev ; Leger, Kasey ; Santos, Maria Verônica ; Sallan, Stephen E. ; Chow, Eric J. / Managing Chemotherapy-Related Cardiotoxicity in Survivors of Childhood Cancers. In: Pediatric Drugs. 2014 ; Vol. 16, No. 5. pp. 373-389.
@article{48b74556fa064564a0780121879ac368,
title = "Managing Chemotherapy-Related Cardiotoxicity in Survivors of Childhood Cancers",
abstract = "In the US, children diagnosed with cancer are living longer, but not without consequences from the same drugs that cured their cancer. In these patients, cardiovascular disease is the leading cause of non-cancer-related morbidity and mortality. Although this review focuses on anthracycline-related cardiomyopathy in childhood cancer survivors, the global lifetime risk of other cardiovascular diseases such as atherosclerosis, arrhythmias and intracardiac conduction abnormalities, hypertension, and stroke also are increased. Besides anthracyclines, newer molecularly targeted agents, such as vascular endothelial growth factor receptor and tyrosine kinase inhibitors, also have been associated with acute hypertension, cardiomyopathy, and increased risk of ischemic cardiac events and arrhythmias, and are summarized here. This review also covers other risk factors for chemotherapy-related cardiotoxicity (including both modifiable and non-modifiable factors), monitoring strategies (including both blood and imaging-based biomarkers) during and following cancer treatment, and discusses the management of cardiotoxicity (including prevention strategies such as cardioprotection by use of dexrazoxane).",
author = "Lipshultz, {Steven E} and Diamond, {Melissa B.} and Franco, {Vivian I.} and Sanjeev Aggarwal and Kasey Leger and Santos, {Maria Ver{\^o}nica} and Sallan, {Stephen E.} and Chow, {Eric J.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s40272-014-0085-1",
language = "English",
volume = "16",
pages = "373--389",
journal = "Pediatric Drugs",
issn = "1174-5878",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - Managing Chemotherapy-Related Cardiotoxicity in Survivors of Childhood Cancers

AU - Lipshultz, Steven E

AU - Diamond, Melissa B.

AU - Franco, Vivian I.

AU - Aggarwal, Sanjeev

AU - Leger, Kasey

AU - Santos, Maria Verônica

AU - Sallan, Stephen E.

AU - Chow, Eric J.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - In the US, children diagnosed with cancer are living longer, but not without consequences from the same drugs that cured their cancer. In these patients, cardiovascular disease is the leading cause of non-cancer-related morbidity and mortality. Although this review focuses on anthracycline-related cardiomyopathy in childhood cancer survivors, the global lifetime risk of other cardiovascular diseases such as atherosclerosis, arrhythmias and intracardiac conduction abnormalities, hypertension, and stroke also are increased. Besides anthracyclines, newer molecularly targeted agents, such as vascular endothelial growth factor receptor and tyrosine kinase inhibitors, also have been associated with acute hypertension, cardiomyopathy, and increased risk of ischemic cardiac events and arrhythmias, and are summarized here. This review also covers other risk factors for chemotherapy-related cardiotoxicity (including both modifiable and non-modifiable factors), monitoring strategies (including both blood and imaging-based biomarkers) during and following cancer treatment, and discusses the management of cardiotoxicity (including prevention strategies such as cardioprotection by use of dexrazoxane).

AB - In the US, children diagnosed with cancer are living longer, but not without consequences from the same drugs that cured their cancer. In these patients, cardiovascular disease is the leading cause of non-cancer-related morbidity and mortality. Although this review focuses on anthracycline-related cardiomyopathy in childhood cancer survivors, the global lifetime risk of other cardiovascular diseases such as atherosclerosis, arrhythmias and intracardiac conduction abnormalities, hypertension, and stroke also are increased. Besides anthracyclines, newer molecularly targeted agents, such as vascular endothelial growth factor receptor and tyrosine kinase inhibitors, also have been associated with acute hypertension, cardiomyopathy, and increased risk of ischemic cardiac events and arrhythmias, and are summarized here. This review also covers other risk factors for chemotherapy-related cardiotoxicity (including both modifiable and non-modifiable factors), monitoring strategies (including both blood and imaging-based biomarkers) during and following cancer treatment, and discusses the management of cardiotoxicity (including prevention strategies such as cardioprotection by use of dexrazoxane).

UR - http://www.scopus.com/inward/record.url?scp=84919905150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919905150&partnerID=8YFLogxK

U2 - 10.1007/s40272-014-0085-1

DO - 10.1007/s40272-014-0085-1

M3 - Article

C2 - 25134924

AN - SCOPUS:84919905150

VL - 16

SP - 373

EP - 389

JO - Pediatric Drugs

JF - Pediatric Drugs

SN - 1174-5878

IS - 5

ER -